Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Luye Pharma Group ( (HK:2186) ) is now available.
Luye Pharma Group Ltd. has announced the current composition of its board of directors, comprising four executive directors, two non-executive directors and five independent non-executive directors, reflecting a diversified governance structure. The company has also detailed the membership and chairmanship of its four key board committees—Audit, Remuneration, Nomination and Environmental, Social and Governance—signalling an emphasis on structured oversight, regulatory compliance and ESG governance that may strengthen investor confidence and corporate transparency.
The most recent analyst rating on (HK:2186) stock is a Hold with a HK$3.50 price target. To see the full list of analyst forecasts on Luye Pharma Group stock, see the HK:2186 Stock Forecast page.
More about Luye Pharma Group
Luye Pharma Group Ltd. is a Bermuda-incorporated pharmaceutical company listed in Hong Kong, focused on the research, development, manufacturing and commercialization of innovative medicines, with a primary market focus on China and international markets for specialty and innovative therapies.
Average Trading Volume: 22,731,099
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$10.92B
For an in-depth examination of 2186 stock, go to TipRanks’ Overview page.